Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis

Cell Proliferation

Volumn 45, Issue 3, 2012, Pages 207-216

  Lin, F ^a   Lin, P ^a   Zhao, D ^a   Chen, Y ^a   Xiao, L ^a   Qin, W ^a   Li, D ^a   Chen, H ^a   Zhao, B ^a   Zou, H ^a   Zheng, X ^a   Yu, X ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BROXURIDINE; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOCORTIN 5; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P27; SURVIVIN; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COLONY FORMING CELL; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MALE; PHASE TRANSITION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING;

ANDROGENS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR ALPHA; UP-REGULATION;

EID: 84859846404     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2012.00812.x     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J. Clin. 60, 277-300.
2. Saleem M, Kweon MH, Johnson JJ, Adhami VM, Elcheva I, Khan Net al. (2006) S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase. Proc. Natl. Acad. Sci. USA 103, 14825-14830.
3. Sasai Y (2001) Roles of Sox factors in neural determination: conserved signaling in evolution? Int. J. Dev. Biol. 45, 321-326.
4. Stevanovic M, Zuffardi O, Collignon J, Lovell-Badge R, Goodfellow P, et al. (1994) The cDNA sequence and chromosomal location of the human SOX2 gene. Mamm. Genome 5, 640-642.
5. Yuan H, Corbi N, Basilico C, Dailey L (1995) Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. Genes Dev. 9, 2635-2645.
6. Bylund M, Andersson E, Novitch BG, Muhr J (2003) Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat. Neurosci. 6, 1162-1168.
7. Wegner M (1999) From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res. 27, 1409-1420.
8. Kamachi Y, Uchikawa M, Kondoh H (2001) Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet. 16, 182-187.
9. Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U, et al. (2005) Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc. Natl. Acad. Sci. USA 102, 9601-9606.
10. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y (2006) Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 32, 164-170.
11. Ben-Porath I, Thomson MW, Carey VJ, Park JH, Park JW, Lee JC, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507.
12. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27, 40-48.
13. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238-1242.
14. Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, et al. (2010) Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J. Urol. 183, 2045-2053.
15. Gure AO, Stockert E, Scanlan MJ, Keresztes RS, Jäger D, Altorki NK, et al. (2000) Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc. Natl. Acad. Sci. USA 97, 4198-4203.
16. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembelé D, et al. (2010) SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS ONE 5, e8960.
17. Ye F, Li Y, Hu Y, Zhou C, Hu Y, Chen H (2010) Expression of Sox2 in human ovarian epithelial carcinoma. J. Cancer Res. Clin. Oncol. 137, 131-137.
18. Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y, et al. (2011) SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J. Mol. Cell Biol. 3, 230-238.
19. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. (2009) Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann. Surg. Oncol. 16, 3488-3498.
20. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, et al. (2009) Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 27, 993-1005.
21. Altieri DC, Marchisio PC (1999) Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab. Invest. 79, 1327-1333.
22. Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581-8589.
23. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y, et al. (2006) Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107, 746-756.
24. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3, 46-54.
25. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, et al. (2004) Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100, 751-757.
26. Liu X, Gao R, Gao L, Gao L, Zhao Y, Zhao L, et al. (2010) Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition. BMC Cancer 10, 418-431.
27. Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, et al. (2007) Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int. J. Cancer 120, 160-169.
28. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL, et al. (2010) Evidence that SOX2 overexpression is oncogenic in the lung. PLoS ONE 5, 11022.
29. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. (2008) The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J. Biol. Chem. 283, 17969-17978.
30. Gusterson BA (1992) Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur. J. Cancer 28, 263-267.
31. Sherr CJ (1994) G1 phase progression: cycling on cue. Cell 79, 551-555.
32. Besson A, Dowdy SF, Roberts JM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 14, 159-169.
33. Mani S, Wang C, Wu K, Francis R, Pestell R (2000) Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin. Investig. Drugs 9, 1849-1870.
34. Shah RB, Ghosh D, Elder JT (2006) Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate 66, 1437-1444.
35. Harris RC, Chung E, Coffey RJ (2003) EGF receptor ligands. Exp. Cell Res. 284, 2-13.
36. Seth D, Shaw K, Jazayeri J, Leedman PJ (2007) Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-αlpha in human prostate cancer cells. Br. J. Cancer 80, 657-669.
37. Seth D, Shaw K, Jazayeri J, Leedman PJ (1999) Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-α in human prostate cancer cells. Br. J. Cancer 80, 657-669.
38. DeHaan AM, Wolters NM, Keller ET, Ignatoski KM (2009) EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate 69, 528-537.
39. Formento P, Hannoun-Levi JM, Gerard F, Mazeau C, Fischel JL, Etienne-Grimaldi MC, et al. (2005) Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur. J. Cancer 41, 1467-1473.
40. Hu Q, Zhang L, Wen J, Wang S, Li M, Feng R, et al. (2010) The EGF receptor-sox2-EGF receptor feedback loop positively regulates the self-renewal of neural precursor cells. Stem Cells 28, 279-286.